



**Qdata® Prostate Cancer is a real-world dataset on more than 643,000 patients with exclusive access to key variables including PSA level, Gleason score, TNM staging, castration resistance and treatment patterns to better understand the patient journey.**

Verana Health® powers urologic research using exclusive real-world data from the American Urological Association (AUA) Quality Registry (AQUA) and other sources, such as medical and pharmacy claims.

✓ **Exclusive Insights into the Prostate Cancer Population**

Only found here

✓ **Unique Understanding of Prostate Cancer Disease Progression**

View prostate cancer biomarkers such as PSA level or Gleason score

✓ **Earlier View into the Prostate Cancer Patient Journey**

View into treatment path choices from urologist electronic health records (EHRs)

## In Qdata Prostate Cancer:


<b>643K+</b> De-identified patients with Prostate Cancer*	<b>2.9</b> Follow up data w/linked claims	<b>467K+</b> De-identified patients linked w/ claims data**
<small>*Defined as patients in AQUA who have ICD-9-CM 185 or ICD-10-CM C61 AND a Gleason score of 6 or above  ** Defined as patients in AQUA who were diagnosed &gt;= 2015 and ICD-9-CM 185 or ICD-10-CM C61 AND a Gleason score of 6 or above and link with at least one open or closed Komodo Health medical/pharmacy claims data. Data current to January 2025.</small>		

## Key Variables


TNM Stage	TNM Stage (Clinical or Pathological)*	Unique Patients in Qdata Prostate Cancer
TNM stages are extracted from unstructured clinical notes at an encounter level and can be used to inform risk stratification. TNM staging is frequently not supplied by the urologist.	T-stage	<b>268,000</b>
	N-stage	<b>120,000</b>
	M-stage	<b>82,000</b>
<small>*These categories are not mutually exclusive</small>		

# Demographics

## Patient Age



## Patient Race



## Metastatic Progression

Metastatic progression refers to the spread of cancer from its original site to other parts of the body. We define a patient as metastatic from NLP approaches on unstructured clinician notes.

### Metastasis (at Any Point in Time)


Metastasis Stage	Estimated Unique Patients in Qdata Prostate Cancer
M0*	75,000
Metastatic (from TNM staging, M1)*	9,200
Metastatic (from clinical documentation)*	40,800
Metastatic Total	42,700

\*Patients are not mutually exclusive

We capture approximately **5x more instances** of metastasis when expanding from the explicit documentation of the TNM staging system to including more implicit types of evidence.

## Gleason Score

Gleason score is curated from clinical notes based on biopsy samples and describes how aggressive the cancer cells are. 100% of patients in Qdata Prostate Cancer have at least one Gleason score captured.



# Qdata Prostate Cancer

## Potential Applications:



## Ways to Engage Us



\* Data current to January 2025. Data counts represented are subject to change.  
Data counts for research purposes are dependent on project scope and feasibility.



## Want to learn more?

Talk to a team member today  
[team@veranahealth.com](mailto:team@veranahealth.com)

[veranahealth.com/uro-request](https://veranahealth.com/uro-request)

## About Verana Health

Verana Health® is revolutionizing patient care and clinical research by unlocking the potential of real-world data. Verana Health has an exclusive real-world data network of 90 million de-identified patients from more than 20,000 clinicians, stemming from its exclusive data partnerships with leading medical societies. Verana Health harnesses deep expertise, secure advanced technology, and direct access to exclusive, near real-time data sources to deliver actionable quality insights that help companies make sense of the data.

For more information, visit [www.veranahealth.com](https://www.veranahealth.com)